U.S. Physical Therapy (USPH)
(Delayed Data from NYSE)
$84.75 USD
+0.30 (0.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $84.72 -0.03 (-0.04%) 6:06 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.75 USD
+0.30 (0.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $84.72 -0.03 (-0.04%) 6:06 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Zacks News
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Lags Q2 Earnings Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -9.88% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 14.29% and 2.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 4.86% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
AMED or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
AMED vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
U.S. Physical Therapy (USPH) Misses Q1 Earnings Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -12.07% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 11.11% and 7.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 3.51% and 3.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Tops Q4 Earnings Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 5.60% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Analysts Estimate U.S. Physical Therapy (USPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LifeStance Health (LFST) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LifeStance Health (LFST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 9.52% and 1.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?